PDCD1 and neoplasm: Treatment with anti-PD-1 antibody combined with regorafenib plus chidamide-k30 significantly enhanced ORR from 30% to 60% in the second ORR assessment, indicating that the immune system was potentially induced for the direct or indirect activation of CD8+ T-cells to attack tumor cells.